BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyxumia lixisenatide: Phase III data

Top-line data from the double-blind, international Phase III GetGoal Duo 1 trial in 446 Type II diabetics inadequately controlled with oral anti-diabetic drugs showed that Lyxumia as an add-on to Lantus insulin glargine and metformin met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo plus Lantus and metformin (p<0.0001). On secondary endpoints, a significantly greater proportion of patients receiving Lyxumia achieved an HbA1c target of <7% at...

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >